Tonix Pharmaceuticals (TNXP) investor relations material

Key achievements and product launch

• Achieved first-in-class approval for a fibromyalgia drug, marking the first such approval in 15 years.

• Q1 marked the first full quarter of sales post-launch, with 5,400 prescriptions and $3.7 million in sales.

• Early sales trends were flat in Q1 but show acceleration in Q2, indicating growing demand.

• Over 2,150 new prescribers and a broad patient base have adopted the product.

• Refill rates and patient persistence are tracking as expected, with positive feedback from both patients and physicians.

Market differentiation and access

• Product is a non-opioid, non-DEA scheduled analgesic, resonating strongly with patients and payers.

• Secured Medicaid coverage in 38 states (55 million lives) and a GPO agreement covering 35 million commercial lives.

• Medicare coverage is expected to be fully realized by 2028 due to formulary timelines, but prior authorizations are being approved.

• Commercial insurance represents about 70% of the market, with Medicaid being a smaller but growing segment.

Commercial strategy and sales force

• Digital marketing initiatives include unbranded campaigns, influencer partnerships, and patient engagement on social media.

• Sales force consists of 100 reps nationwide, with plans to increase density in high-performing areas as access expands.

• Learning from prescriber data to optimize targeting and considering expansion as managed care contracts grow.